Ajanta Pharma Ltd. — AGM Information 2022

Aug 4, 2022

Ajanta House T +91 22 6606 1000 Charkop, Kandivli West, F +91 22 6606 1200 Mumbai 400 067 E info@ajantapharma.com India W www.ajantapharma.com

==> picture [248 x 24] intentionally omitted <==

4[th] August 2022

BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5[th ] Floor, Plot no. Dalal Street, C/1, G Block, Bandra Kurla Complex, Mumbai – 400001 Bandra (East), Mumbai – 400 051 Scrip Code: BSE – AJANTPHARM 532331 Scrip Code: NSE AJANTPHARM EQ

– Re: Regulation 30 Proceedings of Annual General Meeting

Dear Sirs/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith summary of proceedings of 43[rd] Annual General Meeting of the Company held on 4[th] August 2022 through Video- conference/Other Audio-Visual Means.

You are requested to kindly take above information on your records.

Thanking You,

Yours faithfully,

GAURAN Digitally signed G by GAURANG CHINUBHAI SHAH CHINUBH Date: 2022.08.04 AI SHAH 16:41:22 +05'30'

Gaurang Shah VP – Legal and Company Secretary

Encl.: a/a

==> picture [596 x 36] intentionally omitted <==

Corporate Identity Number – L24230MH1979PLC022059

Ajanta House T +91 22 6606 1000 Charkop, Kandivli West, F +91 22 6606 1200 Mumbai 400 067 E info@ajantapharma.com India W www.ajantapharma.com

==> picture [248 x 24] intentionally omitted <==

SUMMARY OF PROCEEDINGS OF 43[RD] ANNUAL GENERAL MEETING

43[rd] Annual General Meeting (AGM) of the Members of the Company was held on 4[th ] August 2022 through Video-conference/Other Audio-Visual Means (VC/OAVM). The meeting commenced at 11.00 a.m. and concluded at 11.39 a.m.

Mr. Mannalal Agrawal, Chairman of the Company, chaired the meeting.

All the Directors including Chairmen of Audit Committee, Nomination and Remuneration Committee and Stakeholders’ Relationship Committee were present at the meeting. The representatives of the Statutory Auditors and Secretarial Auditors were also present at the meeting.

Number of shareholders present in the meeting through Video-conference:

Promoter and Promoter Group	Public	Total
8	39	47

Company Secretary, Mr. Gaurang Shah, informed that the meeting was conducted through VC / OAVM in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. He also gave general instructions regarding participation in the meeting.

Requisite quorum being present, the Chairman called the meeting to order. He welcomed members to the 43[rd] AGM and requested the Managing Director to continue further proceedings.

Managing Director welcomed members to the 43[rd] AGM and then other Directors introduced themselves.

Managing Director then stated that Notice dated 10[th] May 2022, convening the 43[rd] AGM and

annual report for the year ended 31[st ] March 2022 were already circulated to the members electronically and with the permission of members the same were taken as read.

He mentioned that the audit reports of Statutory Auditors and Secretarial Auditors for the financial year 2021-2022, did not contain any qualifications or adverse remarks.

Managing Director then gave brief speech on performance of the Company and other important developments during the Financial Year 2021-2022. He also touched upon performance of the Company for the 1[st] quarter of Financial Year 2022-23.

==> picture [596 x 36] intentionally omitted <==

Corporate Identity Number – L24230MH1979PLC022059

Ajanta House T +91 22 6606 1000 Charkop, Kandivli West, F +91 22 6606 1200 Mumbai 400 067 E info@ajantapharma.com India W www.ajantapharma.com

==> picture [248 x 24] intentionally omitted <==

Thereafter, following items of business as set out in the Notice of AGM, were tabled at the meeting for consideration of members and Managing Director invited speakers who had registered their names, for raising their queries and views on these items and the annual report.

#	Particulars	Resolution required
1.	Adoption of Consolidated and Standalone Financial Statements together with Directors and Auditors Reports thereon for the financial year ended 31stMarch 2022	Ordinary Resolution
2.	Confirm interim dividend as final dividend	OrdinaryResolution
3.	Re-appointment of Mr. Mannalal B. Agrawal, retiringbyrotation	OrdinaryResolution
4.	Re-appointment of StatutoryAuditors for a second term of fiveyears	OrdinaryResolution
5.	Ratifyingremuneration of Cost Auditors for financialyear 2022	OrdinaryResolution

Speaker shareholders were provided facility through VC and Audio-Visual means, to put forth their queries, comments and views.

Few shareholders put forth their queries and views which were responded by the Managing Director.

Managing Director then thanked all the shareholders for attending the meeting and for continued support to the Company. He requested the Company Secretary to make necessary announcements with regard to e-voting.

Company Secretary informed that the Company had provided remote e-voting facility through CDSL, to the shareholders to cast their votes electronically on all the resolutions set out in the Notice convening the meeting. Facility to vote through electronic voting system on all the items set out in the notice, was also made available at the meeting for those shareholders who had not cast their votes through remote e-voting before the meeting.

He further stated that Company had appointed Mr. Alwyn D’Souza, Practising Company Secretary, as Scrutiniser for the purpose of scrutinising the process of remote e-voting held prior and e- voting during the AGM. The results of the remote e-voting and e-voting at the 43[rd] AGM, together with the Report of the Scrutinizers thereon, will be disclosed to the Stock Exchanges and will be displayed on the website of the Company within two working days.

For Ajanta Pharma Ltd.

GAURANG Digitally signed by GAURANG CHINUBHAI CHINUBHAI SHAH SHAH Date: 2022.08.04 16:41:49 +05'30' Gaurang Shah VP – Legal and Company Secretary

Date: 4.08.2022

==> picture [596 x 36] intentionally omitted <==

Corporate Identity Number – L24230MH1979PLC022059